| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
114,470,000 |
| Market
Cap: |
4.73(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$23.65 - $93.31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
517,119 |
788,077 |
1,012,908 |
1,537,097 |
| Total Sell Value |
$30,314,126 |
$47,103,928 |
$62,100,866 |
$94,614,248 |
| Total People Sold |
7 |
13 |
14 |
16 |
| Total Sell Transactions |
10 |
60 |
82 |
157 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Deschatelets Pascal |
Chief Scientific Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
19,634 |
1,003,414 |
|
- |
|
| Chopas James George |
VP/Chief Accounting Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
9,621 |
28,072 |
|
- |
|
| Lewis Karen |
Chief People Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
19,634 |
42,075 |
|
- |
|
| Delong Mark Jeffrey |
Chief Business & Strat Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
19,634 |
48,688 |
|
- |
|
| Townsend Adam J. |
Chief Commercial Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
27,488 |
70,395 |
|
- |
|
| Eisele Jeffrey |
Chief Development Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,580 |
54,230 |
|
- |
|
| Scheibler Lukas |
Chief Research Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,580 |
63,707 |
|
- |
|
| Sullivan Timothy Eugene |
Chief Financial Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
27,488 |
127,141 |
|
- |
|
| Watson David O. |
General Counsel |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
53,455 |
169,024 |
|
- |
|
| Francois Cedric |
Chief Executive Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
83,447 |
1,048,575 |
|
- |
|
| Deschatelets Pascal |
Chief Scientific Officer |
• • – |
2023-01-09 |
4 |
AS |
$46.08 |
$552,960 |
D/D |
(12,000) |
983,780 |
|
84% |
|
| Deschatelets Pascal |
Chief Scientific Officer |
• • – |
2023-01-09 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
995,780 |
|
- |
|
| Grossi Federico |
Chief Medical Officer |
• • – |
2023-01-05 |
4 |
AS |
$48.79 |
$121,975 |
D/D |
(2,500) |
94,884 |
|
84% |
|
| Baumal Caroline |
Chief Medical OfficerOfficer |
• – – |
2023-01-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
133 |
|
75% |
|
| Dunlop A. Sinclair |
Director |
• • – |
2023-01-03 |
4 |
AS |
$50.70 |
$25,350 |
D/D |
(500) |
132,797 |
|
75% |
|
| Baumal Caroline |
Chief Medical Officer |
• • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
35,549 |
35,682 |
|
- |
|
| Townsend Adam J. |
Chief Commercial Officer |
• • – |
2023-01-03 |
4 |
AS |
$50.70 |
$253,500 |
D/D |
(5,000) |
42,907 |
|
75% |
|
| Townsend Adam J. |
Chief Commercial Officer |
• • – |
2023-01-03 |
4 |
OE |
$15.09 |
$75,450 |
D/D |
5,000 |
47,907 |
|
- |
|
| Dunlop A. Sinclair |
Director |
– • – |
2023-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,867 |
133,297 |
|
- |
|
| Machiels Alec |
Director |
– • – |
2023-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,867 |
267,641 |
|
- |
|
| Chan Gerald |
Director |
– • – |
2023-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,867 |
8,097 |
|
- |
|
| Fonteyne Paul R. |
Director |
– • – |
2023-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,867 |
13,097 |
|
- |
|
| Obrien Stephanie Monaghan |
Director |
– • – |
2023-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,867 |
8,097 |
|
- |
|
| Deschatelets Pascal |
Chief Scientific Officer |
• • – |
2022-12-29 |
4 |
OE |
$3.67 |
$25,690 |
D/D |
7,000 |
977,280 |
|
- |
|
| Eisele Jeffrey |
Exec VP, Program Team Lead |
• • – |
2022-12-22 |
4 |
D |
$51.68 |
$4,600 |
D/D |
(89) |
31,650 |
|
- |
|
714 Records found
|
|
Page 11 of 29 |
|
|
0.69 (1.64%) 
